FIELD: biotechnology; medicine.
SUBSTANCE: group of inventions relates to a stable pharmaceutical preparation of PD-1 antibody and use thereof. Disclosed is a stable pharmaceutical preparation of PD-1 antibody containing 1 mg/ml to 60 mg/ml of PD-1 antibody or antigen-binding fragment thereof, from 30 mg/ml to 120 mg/ml α,α-trehalose dihydrate, from 0.01 mg/ml to 1 mg/ml polysorbate 20, from 2 mM to 30 mM acetate buffer. PH of the preparation ranges from 4.5 to 6.0. Antibody to PD-1 contains amino acid sequence of heavy chain with SEQ ID NO: 7 and light chain amino acid sequence with SEQ ID NO: 8. Also disclosed is a lyophilised powder prepared by lyophilisation of a pharmaceutical preparation at a drying temperature of −10 °C to −5 °C.
EFFECT: obtained preparation is applicable in a method of preventing or treating a PD-1-mediated disease or disorder; invention provides effective inhibition of aggregation and deamidation of PD-1 antibody, thereby preventing antibody degradation, producing a stable pharmaceutical preparation for injections; antibody to PD-1 remains stable even after re-dissolution after lyophilisation.
14 cl, 2 dwg, 5 tbl, 8 ex
Title |
Year |
Author |
Number |
PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO SOST, AND ITS USE |
2018 |
- Fang Jingjing
- Yan Zhen
- Liu Xun
|
RU2779430C2 |
PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION |
2018 |
- Yan, Zhen
- Yang, Jianjian
- Yan, Xiaodan
- Wu, Shan
- Liu, Xun
|
RU2766590C2 |
PHARMACEUTICAL COMPOSITION BASED ON IL-15 PROTEIN COMPLEX AND APPLICATIONS THEREOF |
2018 |
- U, Tintin
- Li, Khao
- Lyu, Syun
|
RU2749342C1 |
PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION |
2019 |
- Tyan, Chenmin
- Li, Khao
- Lyu, Syun
|
RU2791683C2 |
PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF |
2019 |
- Yang, Jianjian
- Li, Hao
- Liu, Xun
- Jiang, Jiahua
|
RU2778572C1 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO LAG-3 AND ITS USE |
2018 |
- Wu Tingting
- Li Hao
- Liu Xun
- Fu Yayuan
|
RU2771384C2 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE |
2018 |
- Tian, Chenmin
- Li, Hao
- Liu, Xun
|
RU2782792C2 |
USE OF COMBINATION OF ANTIBODY TO PD-1 AND VEGFR INHIBITOR IN PRODUCTION OF DRUG FOR TREATMENT OF MALIGNANT NEOPLASMS |
2017 |
- Sun, Sin
- Tsao, Gotsin
- Yan, Chanyun
- Chzhan, Lyanshan
- Go, Yun
|
RU2762746C2 |
APPLICATION OF AN ANTIBODY TO PD-1 IN COMBINATION WITH FAMITINIB FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING TUMOURS |
2019 |
- Zhang Lianshan
- Yang Qing
- Wang Quanren
- Huang Xiaoxing
- Liao Cheng
- Yang Changyong
- Ye Dingwei
- Wu Xiaohua
|
RU2783846C1 |
FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE |
2018 |
- Gu, Tszinmin
- Lo, Syao
- Tao, Vejkan
|
RU2776204C1 |